Overview

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior secondary androgen receptor signaling inhibitor therapy (eg, abiraterone, enzalutamide, apalutamide).

Phase:

Phase 1

Details

Lead Sponsor:

Parker Institute for Cancer Immunotherapy

Collaborators:

Bristol-Myers Squibb
Cancer Research Institute, New York City
Celldex Therapeutics
Inovio Pharmaceuticals
Nektar Therapeutics
Oncovir, Inc.

Treatments:

Antibodies, Monoclonal
Carboxymethylcellulose Sodium
Nivolumab
Poly I-C
Poly ICLC